CD274 and nasopharyngeal carcinoma: Patients were recruited based on eligible criteria such as those having tumor with PD-L1+ NPC, those who did or did not receive prior standard therapy or was deemed ineffective or inappopriate, those aged ≥ 18 years old, those with ECOG performance status of 0 or 1, and those with adequate organ function.